- 著者
- Hayato Fujioka Kota Kakeshita Teruhiko Imamura Yu Arisawa Shingo Yokoyama Hidenori Yamazaki Tsutomu Koike Takashi Minamisaka Kenichi Hirabayashi Koichiro Kinugawa
- 出版者
- The Japanese Society of Internal Medicine
- 雑誌
- Internal Medicine (ISSN:09182918)
- 巻号頁・発行日
- pp.1918-23, (Released:2023-06-28)
- 参考文献数
- 14
- 被引用文献数
- 2
Pembrolizumab, an immune checkpoint inhibitor, is used to treat a variety of refractory malignancies. However, these agents are sometimes associated with immune-related adverse events. A 71-year-old woman received pembrolizumab-integrated chemotherapy to treat her recurrent mandibular gingival cancer. Five months after stopping pembrolizumab, she developed acute tubulointerstitial nephritis associated with Fanconi syndrome and type 1 renal tubular acidosis, which resolved with steroid therapy. We experienced a case of pembrolizumab-induced Fanconi syndrome and type 1 renal acidosis. We recommend follow-up of the tubular function in addition to the renal function even after discontinuation of pembrolizumab.